Cargando…

Real-world effectiveness of antidepressant use in persons with schizophrenia: within-individual study of 61,889 subjects

The aim of this study was to investigate the real-world effectiveness of antidepressant use in persons with schizophrenia. The register-based study cohort included all 61,889 persons treated in inpatient care due to schizophrenia during 1972–2014 in Finland. The main outcome was hospitalization due...

Descripción completa

Detalles Bibliográficos
Autores principales: Puranen, Arto, Koponen, Marjaana, Lähteenvuo, Markku, Tanskanen, Antti, Tiihonen, Jari, Taipale, Heidi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10220047/
https://www.ncbi.nlm.nih.gov/pubmed/37236980
http://dx.doi.org/10.1038/s41537-023-00364-x
_version_ 1785049135124054016
author Puranen, Arto
Koponen, Marjaana
Lähteenvuo, Markku
Tanskanen, Antti
Tiihonen, Jari
Taipale, Heidi
author_facet Puranen, Arto
Koponen, Marjaana
Lähteenvuo, Markku
Tanskanen, Antti
Tiihonen, Jari
Taipale, Heidi
author_sort Puranen, Arto
collection PubMed
description The aim of this study was to investigate the real-world effectiveness of antidepressant use in persons with schizophrenia. The register-based study cohort included all 61,889 persons treated in inpatient care due to schizophrenia during 1972–2014 in Finland. The main outcome was hospitalization due to psychosis and secondary outcomes included non-psychiatric hospitalization and all-cause mortality. We used within-individual design to compare the risk of hospitalization-based outcomes during the time periods of antidepressant use to antidepressant non-use periods within the same person, and traditional between-individual Cox models for mortality. The risk of psychosis hospitalization was lower during antidepressant use as compared to non-use (adjusted Hazard Ratio, aHR, 0.93, 95% CI 0.92–0.95). Antidepressants were associated with a decreased risk of mortality (aHR 0.80, 95% CI 0.76–0.85) and a slightly increased risk of non-psychiatric hospitalization (aHR 1.03, 95% CI 1.01–1.06). In conclusion, these results indicate that antidepressants might be useful and relatively safe to use in this population.
format Online
Article
Text
id pubmed-10220047
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-102200472023-05-28 Real-world effectiveness of antidepressant use in persons with schizophrenia: within-individual study of 61,889 subjects Puranen, Arto Koponen, Marjaana Lähteenvuo, Markku Tanskanen, Antti Tiihonen, Jari Taipale, Heidi Schizophrenia (Heidelb) Article The aim of this study was to investigate the real-world effectiveness of antidepressant use in persons with schizophrenia. The register-based study cohort included all 61,889 persons treated in inpatient care due to schizophrenia during 1972–2014 in Finland. The main outcome was hospitalization due to psychosis and secondary outcomes included non-psychiatric hospitalization and all-cause mortality. We used within-individual design to compare the risk of hospitalization-based outcomes during the time periods of antidepressant use to antidepressant non-use periods within the same person, and traditional between-individual Cox models for mortality. The risk of psychosis hospitalization was lower during antidepressant use as compared to non-use (adjusted Hazard Ratio, aHR, 0.93, 95% CI 0.92–0.95). Antidepressants were associated with a decreased risk of mortality (aHR 0.80, 95% CI 0.76–0.85) and a slightly increased risk of non-psychiatric hospitalization (aHR 1.03, 95% CI 1.01–1.06). In conclusion, these results indicate that antidepressants might be useful and relatively safe to use in this population. Nature Publishing Group UK 2023-05-26 /pmc/articles/PMC10220047/ /pubmed/37236980 http://dx.doi.org/10.1038/s41537-023-00364-x Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Puranen, Arto
Koponen, Marjaana
Lähteenvuo, Markku
Tanskanen, Antti
Tiihonen, Jari
Taipale, Heidi
Real-world effectiveness of antidepressant use in persons with schizophrenia: within-individual study of 61,889 subjects
title Real-world effectiveness of antidepressant use in persons with schizophrenia: within-individual study of 61,889 subjects
title_full Real-world effectiveness of antidepressant use in persons with schizophrenia: within-individual study of 61,889 subjects
title_fullStr Real-world effectiveness of antidepressant use in persons with schizophrenia: within-individual study of 61,889 subjects
title_full_unstemmed Real-world effectiveness of antidepressant use in persons with schizophrenia: within-individual study of 61,889 subjects
title_short Real-world effectiveness of antidepressant use in persons with schizophrenia: within-individual study of 61,889 subjects
title_sort real-world effectiveness of antidepressant use in persons with schizophrenia: within-individual study of 61,889 subjects
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10220047/
https://www.ncbi.nlm.nih.gov/pubmed/37236980
http://dx.doi.org/10.1038/s41537-023-00364-x
work_keys_str_mv AT puranenarto realworldeffectivenessofantidepressantuseinpersonswithschizophreniawithinindividualstudyof61889subjects
AT koponenmarjaana realworldeffectivenessofantidepressantuseinpersonswithschizophreniawithinindividualstudyof61889subjects
AT lahteenvuomarkku realworldeffectivenessofantidepressantuseinpersonswithschizophreniawithinindividualstudyof61889subjects
AT tanskanenantti realworldeffectivenessofantidepressantuseinpersonswithschizophreniawithinindividualstudyof61889subjects
AT tiihonenjari realworldeffectivenessofantidepressantuseinpersonswithschizophreniawithinindividualstudyof61889subjects
AT taipaleheidi realworldeffectivenessofantidepressantuseinpersonswithschizophreniawithinindividualstudyof61889subjects